查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102651

肝纖維化治療市場預測至2034年－全球分析（依療法、藥物類別、作用機制、疾病階段、給藥途徑、通路及地區分類）

Liver Fibrosis Treatment Market Forecasts To 2034 - Global Analysis Treatment Type, Drug Class, Mechanism of Action, Stage of Disease, Route of Administration, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球肝纖維化治療市場規模將達到 235 億美元，並在預測期內以 12.5% 的複合年成長率成長，到 2034 年將達到 604 億美元。

肝纖維化的治療重點在於減緩、預防或逆轉肝臟瘢痕組織的積累，這種積累是由病毒性肝炎、酒精攝入和代謝紊亂等慢性損傷引起的。目前的治療方法包括針對病因進行治療、使用抗病毒藥物、改變生活方式以及採用新型抗纖維化療法。研發的進展正推動著標靶治療抑制纖維化或促進組織修復。早期診斷對於改善治療效果至關重要，正在進行的臨床試驗正在擴大治療選擇，並改善肝纖維化早期和晚期患者的預後。

增加對研發和臨床試驗的投入

來自產業相關人員、政府和研究機構的資金投入不斷增加，推動了肝纖維化治療的進展。對科學研究和臨床開發的巨額投資，使研究人員能夠更深入地了解纖維化機制，並發現新的治療標靶。臨床試驗活動的激增，豐富了開發平臺，創造了充滿希望的未來前景。生技公司與學術機構合作的加強，進一步加速了創新。資金的湧入，增強了產品研發能力，促進了長期市場擴張，並為下一代療法更有效率地惠及病患創造了機會。

醫療成本不斷上漲以及經濟負擔的極限

治療肝纖維化所需的高昂費用，包括創新藥物、診斷程序和持續監測，對患者和醫療保健系統構成重大障礙。許多新療法價格昂貴，使得很大一部分人群，尤其是在資源匱乏的地區，難以負擔。報銷不足和保險覆蓋範圍有限加劇了經濟負擔，阻礙了及時治療。這些經濟限制導致治療接受率降低、療程不完整以及診斷延誤，進而阻礙了醫療預算有限地區的整體市場擴張，並限制了患者獲得先進醫療服務的機會。

對非侵入性診斷解決方案的需求日益成長

向無創且對患者更友善的診斷方法的轉變，正在為肝纖維化市場開闢新的成長途徑。先進的影像技術和生物標記檢測能夠提供可靠的結果，避免傳統切片檢查帶來的不適和風險。這將使更多人接受篩檢，並實現肝纖維化的早期發現。隨著檢出率的提高，可治療的患者數量將顯著增加。這一趨勢將促進治療方案的普及，推動診斷和治療方法的創新，並最終改善疾病管理，擴大市場潛力。

因副作用導致治療中斷率高

安全隱患和不良副作用導致許多肝纖維化患者過早停止治療，對市場表現構成重大威脅。諸如胃腸道不適、疲勞或肝臟併發症風險等副作用會使患者猶豫是否繼續治療。這降低了治療成功率，並削弱了人們對新藥的信心。醫生也可能不願開立已知依從性差的藥物。較低的依從率會導致用藥量減少，進而限制新療法的推廣應用，並削弱針對肝纖維化的創新解決方案的市場前景。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為肝纖維化治療市場帶來了挑戰與機會。疫情初期，各項限制措施導致患者就診量減少、診斷延誤、臨床試驗進展受阻，治療計畫的改善也受到阻礙。許多肝病患者因無法獲得常規醫療服務而病情加重。另一方面，新冠疫情凸顯了肝臟的脆弱性，並促使人們對更先進的診斷工具和監測系統更加關注。遠端醫療和非侵入性檢測的普及應用，加強了對患者的長期照護。儘管市場面臨一些暫時的挑戰，但人們對肝臟健康的日益重視以及數位醫療的融合，為未來的市場成長提供了支撐。

在預測期內，「製藥」領域預計將佔據最大的市場佔有率。

由於其廣泛的可及性和在臨床實踐中長期發揮的作用，預計在預測期內，藥品領域將佔據最大的市場佔有率。這些藥物主要針對感染疾病、代謝紊亂和促進纖維化的發炎過程等潛在病因。給藥方便，尤其是口服製劑的普及，有助於提高患者依從性並促進其廣泛應用。製劑的不斷改進進一步增強了其在延緩疾病進展方面的治療價值。與更新、更複雜的療法相比，這些藥物價格適中且非常實用，必將在全球不同的醫療保健環境中保持其主導地位。

在預測期內，「線上藥局」細分市場預計將實現最高的複合年成長率。

在預測期內，受便捷易用的藥品服務需求不斷成長的推動，線上藥局預計將成為肝纖維化治療市場中成長最快的細分市場。患者越來越傾向於在線訂購藥品，尤其是長期疾病患者，因為宅配服務、節省時間且方便快捷。遠端醫療服務和電子處方箋的普及進一步推動了線上藥局的普及。這些平台通常提供價格優勢和私密的購買選項，使其成為眾多患者的理想選擇。隨著數位醫療系統的不斷發展，線上藥局正成為未來市場成長的關鍵管道。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其完善的醫療保健體系、較高的疾病認知度以及大型製藥企業的存在。該地區受益於先進醫療療法的快速推廣和廣泛的篩檢項目，這些都有助於早期診斷。保險覆蓋範圍和報銷機制也提高了患者獲得治療的機會。慢性肝病盛行率的上升推動了對有效療法的需求。此外，對生物醫學研究的大力投入和活躍的臨床試驗環境也促進了創新。這些因素共同作用，預計將使北美繼續保持在全球市場的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於患者群體的快速成長和肝臟相關疾病發生率的上升。病毒性肝炎的流行、不健康的生活方式以及代謝性疾病等因素正在推動治療需求。除了醫療保健系統的改善外，政府的大力支持和宣傳活動也提高了早期診斷率和醫療服務的可近性。此外，跨國製藥公司正在增加對該地區的投資，尤其是在印度、中國和日本等重點國家，這有助於先進療法的推廣，並推動市場強勁成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球肝纖維化治療市場：依治療類型分類

  • 製藥
    • 抗纖維化藥物
    • 抗發炎藥
    • 抗病毒藥物
    • 其他藥物
  • 生物製藥和先進療法
    • 單株抗體
    • 基因和細胞療法
  • 聯合治療
  • 支持性護理

第6章 全球肝纖維化治療市場：依藥物類別分類

  • 低分子化合物
  • 胜肽
  • 重組蛋白
  • 疫苗

第7章 全球肝纖維化治療市場：依作用機轉分類

  • 纖維化抑制劑
  • 促進纖維化的藥物
  • 代謝調節劑
  • 抗氧化途徑調節劑

第8章 全球肝纖維化治療市場：依疾病進展階段分類

  • 早期（F0-F2）
  • 晚期

第9章 全球肝纖維化治療市場：依給藥途徑分類

  • 口服
  • 注射藥物
  • 靜脈
  • 外用

第10章 全球肝纖維化治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 診所和專科醫療中心

第11章 全球肝纖維化治療市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Takeda Pharmaceutical Company Limited
  • Intercept Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Akero Therapeutics, Inc.
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Inventiva SA
  • Enanta Pharmaceuticals, Inc.
Product Code: SMRC38430

According to Stratistics MRC, the Global Liver Fibrosis Treatment Market is accounted for $23.5 billion in 2026 and is expected to reach $60.4 billion by 2034 growing at a CAGR of 12.5% during the forecast period. Liver fibrosis treatment focuses on slowing, halting, or reversing the accumulation of scar tissue in the liver caused by chronic injury such as viral hepatitis, alcohol use, or metabolic disorders. Current approaches include addressing the underlying cause, using antiviral drugs, lifestyle modifications, and emerging anti-fibrotic therapies. Advances in research are driving the development of targeted drugs that inhibit fibrogenesis or promote tissue repair. Early diagnosis plays a critical role in improving outcomes, while ongoing clinical trials continue to expand treatment options and enhance patient prognosis in both early and advanced stages of liver fibrosis.

Market Dynamics:

Driver:

Increasing Investments in R&D and Clinical Trials

Growing financial support from industry players, governments, and research organizations is propelling advancements in liver fibrosis therapeutics. Substantial investments in scientific studies and clinical development are helping researchers better understand the fibrotic process and identify new therapeutic targets. With a surge in clinical trial activities, the treatment pipeline is becoming more diverse and promising. Increased collaboration between biotech firms and academic institutions further accelerates innovation. This influx of capital strengthens product development, stimulates long-term market expansion, and creates opportunities for next-generation therapies to reach patients more efficiently.

Restraint:

High Cost of Treatment and Limited Affordability

The elevated expenses associated with liver fibrosis management, including innovative drugs, diagnostic procedures, and ongoing monitoring, create a significant hurdle for patients and healthcare systems. Many newer therapies are priced at premium levels, making them inaccessible to a large portion of the population, particularly in resource-limited regions. Reimbursement gaps and restricted insurance support worsen affordability problems, discouraging timely treatment. These financial limitations lead to lower adoption rates, incomplete therapy cycles, and delayed diagnosis, collectively hindering overall market expansion and limiting access to advanced care in regions with constrained healthcare budgets.

Opportunity:

Rising Demand for Non-Invasive Diagnostic Solutions

The shift toward non-invasive and patient-friendly diagnostic methods is opening new avenues for growth in the liver fibrosis market. Advanced imaging techniques and biomarker tests provide reliable results without the discomfort and risks associated with traditional biopsies. This encourages more individuals to undergo screening, leading to earlier identification of fibrosis. As detection rates improve, the number of patients eligible for treatment rises significantly. This trend supports the adoption of therapeutic solutions and fosters innovation in combined diagnostic-treatment approaches, ultimately enhancing disease management and expanding market potential.

Threat:

High Treatment Dropout Rates Due to Adverse Effects

Safety-related issues and uncomfortable side effects cause many liver fibrosis patients to discontinue treatment early, posing a major threat to market performance. Adverse reactions such as gastrointestinal discomfort, fatigue, or potential liver complications make patients hesitant to continue therapy. This lowers treatment success rates and reduces confidence in new drugs. Physicians may also be reluctant to prescribe medications with known compliance challenges. As adherence drops, usage declines, limiting the overall adoption of emerging therapies and weakening the market outlook for innovative fibrosis-targeting solutions.

Covid-19 Impact:

The COVID-19 pandemic created both challenges and opportunities for the liver fibrosis treatment market. Early in the outbreak, restrictions led to fewer medical consultations, delayed diagnoses, and disruptions in clinical trial progress, slowing therapeutic advancements. Many liver patients experienced disease progression due to reduced access to routine care. At the same time, COVID-19 highlighted liver vulnerability, prompting interest in improved diagnostic tools and monitoring systems. Telehealth adoption and non-invasive testing gained momentum, strengthening long-term patient care. Although the market experienced temporary hurdles, the heightened awareness of liver health and digital healthcare integration supported future market growth.

The Pharmaceutical Drugs segment is expected to be the largest during the forecast period

The Pharmaceutical Drugs segment is expected to account for the largest market share during the forecast period, because of their broad accessibility and long-standing role in clinical practice. These medications mainly target root causes like infections, metabolic imbalances, and inflammatory processes that drive fibrosis. Their ease of administration, particularly oral options, supports better patient adherence and widespread usage. Ongoing improvements in drug formulations continue to increase their therapeutic value in controlling disease progression. Compared to newer and more complex treatments, these drugs remain more affordable and practical, ensuring their continued dominance across diverse healthcare environments worldwide.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Pharmacies segment is predicted to witness the highest growth rate within the liver fibrosis treatment market, driven by rising demand for convenient and accessible medication services. Patients increasingly prefer ordering treatments online due to home delivery, time savings, and ease of use, especially for long-term conditions. The expansion of telehealth services and electronic prescriptions is further boosting adoption. These platforms often provide cost advantages and discreet purchasing options, making them appealing to a wide patient base. With continuous advancements in digital healthcare systems, online pharmacies are becoming a key channel for future market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because of its well-developed healthcare system, strong disease awareness, and presence of major drug manufacturers. The region quickly adopts advanced medical therapies and benefits from extensive screening programs that support early diagnosis. Insurance coverage and reimbursement systems also improve patient access to treatment. The rising incidence of chronic liver disorders increases demand for effective therapies. In addition, strong investment in biomedical research and an active clinical trial environment drive innovation. These combined factors ensure North America maintains its leading position in the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by a rapidly expanding patient base and increasing incidence of liver-related disorders. Factors such as viral hepatitis prevalence, unhealthy lifestyles, and metabolic diseases are fueling treatment demand. Improvements in healthcare systems, along with stronger government support and awareness programs, are enhancing early diagnosis and care access. Furthermore, multinational pharmaceutical firms are increasingly investing in this region, particularly in major countries like India, China, and Japan, boosting availability of advanced therapeutic solutions and driving strong market expansion.

Key players in the market

Some of the key players in Liver Fibrosis Treatment Market include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Akero Therapeutics, Inc., FibroGen, Inc., Galectin Therapeutics, Inc., Inventiva S.A., and Enanta Pharmaceuticals, Inc.

Key Developments:

In June 2025, Enanta confirmed that its collaboration with AbbVie continues to support worldwide development and commercialization of MAVYRET(R)/MAVIRET(R) (glecaprevir/pibrentasvir), a direct-acting antiviral regimen originally discovered by Enanta, with AbbVie receiving expanded labeling for acute HCV in the U.S.

In March 2025, Roche entered an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as part of its broader cardiometabolic portfolio.

In January 2025, Intercept renewed its long-standing research and development collaboration with Tes Pharma to continue joint work on bile acid derivatives for liver disease treatment.

Treatment Type Covered:

  • Pharmaceutical Drugs
  • Biologics & Advanced Therapies
  • Combination Therapies
  • Adjunctive Treatments

Drug Class Covered:

  • Small Molecules
  • Peptides
  • Recombinant Proteins
  • Vaccines

Mechanism of Action Covered:

  • Inhibitors of Fibrogenesis
  • Agents Promoting Fibrolysis
  • Metabolic Modulators
  • Anti-Oxidative Pathway Modulators

Stage of Disease Covered:

  • Early Stage (F0-F2)
  • Advanced Stage

Route of Administration Covered:

  • Oral
  • Injectable
  • Intravenous
  • Topical

Distribution Channel Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics & Specialty Centers

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Liver Fibrosis Treatment Market, By Treatment Type

  • 5.1 Pharmaceutical Drugs
    • 5.1.1 Anti-Fibrotic Agents
    • 5.1.2 Anti-Inflammatory Drugs
    • 5.1.3 Antiviral Therapeutics
    • 5.1.4 Other Pharmaceutical Drugs
  • 5.2 Biologics & Advanced Therapies
    • 5.2.1 Monoclonal Antibodies
    • 5.2.2 Gene & Cell-Based Therapy
  • 5.3 Combination Therapies
  • 5.4 Supportive

6 Global Liver Fibrosis Treatment Market, By Drug Class

  • 6.1 Small Molecules
  • 6.2 Peptides
  • 6.3 Recombinant Proteins
  • 6.4 Vaccines

7 Global Liver Fibrosis Treatment Market, By Mechanism of Action

  • 7.1 Inhibitors of Fibrogenesis
  • 7.2 Agents Promoting Fibrolysis
  • 7.3 Metabolic Modulators
  • 7.4 Anti-Oxidative Pathway Modulators

8 Global Liver Fibrosis Treatment Market, By Stage of Disease

  • 8.1 Early Stage (F0-F2)
  • 8.2 Advanced Stage

9 Global Liver Fibrosis Treatment Market, By Route of Administration

  • 9.1 Oral
  • 9.2 Injectable
  • 9.3 Intravenous
  • 9.4 Topical

10 Global Liver Fibrosis Treatment Market, By Distribution Channel

  • 10.1 Hospital Pharmacies
  • 10.2 Retail Pharmacies
  • 10.3 Online Pharmacies
  • 10.4 Clinics & Specialty Centers

11 Global Liver Fibrosis Treatment Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Gilead Sciences, Inc.
  • 14.2 Merck & Co., Inc.
  • 14.3 Bristol-Myers Squibb Company
  • 14.4 Johnson & Johnson
  • 14.5 Novartis AG
  • 14.6 Pfizer Inc.
  • 14.7 AbbVie Inc.
  • 14.8 AstraZeneca PLC
  • 14.9 F. Hoffmann-La Roche Ltd
  • 14.10 Boehringer Ingelheim International GmbH
  • 14.11 Takeda Pharmaceutical Company Limited
  • 14.12 Intercept Pharmaceuticals, Inc.
  • 14.13 Madrigal Pharmaceuticals, Inc.
  • 14.14 Akero Therapeutics, Inc.
  • 14.15 FibroGen, Inc.
  • 14.16 Galectin Therapeutics, Inc.
  • 14.17 Inventiva S.A.
  • 14.18 Enanta Pharmaceuticals, Inc.

List of Tables

  • Table 1 Global Liver Fibrosis Treatment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Liver Fibrosis Treatment Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 3 Global Liver Fibrosis Treatment Market Outlook, By Pharmaceutical Drugs (2023-2034) ($MN)
  • Table 4 Global Liver Fibrosis Treatment Market Outlook, By Anti-Fibrotic Agents (2023-2034) ($MN)
  • Table 5 Global Liver Fibrosis Treatment Market Outlook, By Anti-Inflammatory Drugs (2023-2034) ($MN)
  • Table 6 Global Liver Fibrosis Treatment Market Outlook, By Antiviral Therapeutics (2023-2034) ($MN)
  • Table 7 Global Liver Fibrosis Treatment Market Outlook, By Other Pharmaceutical Drugs (2023-2034) ($MN)
  • Table 8 Global Liver Fibrosis Treatment Market Outlook, By Biologics & Advanced Therapies (2023-2034) ($MN)
  • Table 9 Global Liver Fibrosis Treatment Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 10 Global Liver Fibrosis Treatment Market Outlook, By Gene & Cell-Based Therapy (2023-2034) ($MN)
  • Table 11 Global Liver Fibrosis Treatment Market Outlook, By Combination Therapies (2023-2034) ($MN)
  • Table 12 Global Liver Fibrosis Treatment Market Outlook, By Supportive (2023-2034) ($MN)
  • Table 13 Global Liver Fibrosis Treatment Market Outlook, By Drug Class (2023-2034) ($MN)
  • Table 14 Global Liver Fibrosis Treatment Market Outlook, By Small Molecules (2023-2034) ($MN)
  • Table 15 Global Liver Fibrosis Treatment Market Outlook, By Peptides (2023-2034) ($MN)
  • Table 16 Global Liver Fibrosis Treatment Market Outlook, By Recombinant Proteins (2023-2034) ($MN)
  • Table 17 Global Liver Fibrosis Treatment Market Outlook, By Vaccines (2023-2034) ($MN)
  • Table 18 Global Liver Fibrosis Treatment Market Outlook, By Mechanism of Action (2023-2034) ($MN)
  • Table 19 Global Liver Fibrosis Treatment Market Outlook, By Inhibitors of Fibrogenesis (2023-2034) ($MN)
  • Table 20 Global Liver Fibrosis Treatment Market Outlook, By Agents Promoting Fibrolysis (2023-2034) ($MN)
  • Table 21 Global Liver Fibrosis Treatment Market Outlook, By Metabolic Modulators (2023-2034) ($MN)
  • Table 22 Global Liver Fibrosis Treatment Market Outlook, By Anti-Oxidative Pathway Modulators (2023-2034) ($MN)
  • Table 23 Global Liver Fibrosis Treatment Market Outlook, By Stage of Disease (2023-2034) ($MN)
  • Table 24 Global Liver Fibrosis Treatment Market Outlook, By Early Stage (F0-F2) (2023-2034) ($MN)
  • Table 25 Global Liver Fibrosis Treatment Market Outlook, By Advanced Stage (F3-F4/Cirrhosis) (2023-2034) ($MN)
  • Table 26 Global Liver Fibrosis Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 27 Global Liver Fibrosis Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 28 Global Liver Fibrosis Treatment Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 29 Global Liver Fibrosis Treatment Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 30 Global Liver Fibrosis Treatment Market Outlook, By Topical (2023-2034) ($MN)
  • Table 31 Global Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 32 Global Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 33 Global Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 34 Global Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 35 Global Liver Fibrosis Treatment Market Outlook, By Clinics & Specialty Centers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.